We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Progress Reported in Development of Gene Editing Tool

By LabMedica International staff writers
Posted on 21 Aug 2017
Print article
Image: Photomicrographs of muscle cells from a patient with myotonic dystrophy type I, untreated (left) and treated with the RNA-targeting Cas9 system (right). The MBNL1 protein is in green, repetitive RNA in red and the cell\'s nucleus in blue (Photo courtesy of the University of California, San Diego).
Image: Photomicrographs of muscle cells from a patient with myotonic dystrophy type I, untreated (left) and treated with the RNA-targeting Cas9 system (right). The MBNL1 protein is in green, repetitive RNA in red and the cell\'s nucleus in blue (Photo courtesy of the University of California, San Diego).
Progress has been reported in the effort to develop a CRISPR/Cas9 gene editing tool to be used for modifying RNA rather than the usual target DNA.

CRISPR/Cas9 is regarded as the cutting edge of molecular biology technology. CRISPRs (clustered regularly interspaced short palindromic repeats) are segments of prokaryotic DNA containing short repetitions of base sequences. Each repetition is followed by short segments of "spacer DNA" from previous exposures to a bacterial virus or plasmid. CRISPRs are found in approximately 40% of sequenced bacteria genomes and 90% of sequenced archaea. CRISPRs are often associated with cas genes that code for proteins related to CRISPRs.

Since 2013, the CRISPR/Cas9 system has been used in research for gene editing (adding, disrupting, or changing the sequence of specific genes) and gene regulation. By delivering the Cas9 enzyme and appropriate guide RNAs into a cell, the organism's genome can be cut at any desired location. The conventional CRISPR/Cas9 system is composed of two parts: the Cas9 enzyme, which cleaves the DNA molecule and specific RNA guides that shepherd the Cas9 protein to the target gene on a DNA strand. In 2016, investigators at the University of California, San Diego (USA) reported the design of an RNA-targeting Cas9 (RCas9).

Microsatellite repeat expansions in DNA produce pathogenic RNA species that cause dominantly inherited diseases such as myotonic dystrophy type 1 and 2 (DM1/2), Huntington’s disease, and C9orf72-linked amyotrophic lateral sclerosis (C9-ALS). Means to target these repetitive RNAs are required for diagnostic and therapeutic purposes.

In a study published in the August 10, 2017, online edition of the journal Cell, the University of California, San Diego investigators described the development of a programmable CRISPR system capable of specifically visualizing and eliminating these toxic RNAs. RCas9 worked similarly to the regular CRISP/Cas9 editing tool, but the guide RNA directed the Cas9 enzyme to an RNA molecule instead of DNA.

The investigators reported that RCas9 eliminated 95% or more of the RNA foci linked to myotonic dystrophy type 1 and type 2, C9-ALS, and Huntington's disease. The approach also eliminated 95% of the aberrant repeat RNAs in myotonic dystrophy patient cells cultures.

In another step forward, the investigators produced a truncated version of Cas9 that could be packaged into an adeno-associated virus transport vehicle. This smaller version of Cas9 was created by deleting regions of the protein that were necessary for DNA cleavage, but dispensable for binding RNA.

"This is exciting because we are not only targeting the root cause of diseases for which there are no current therapies to delay progression, but we have re-engineered the CRISPR/Cas9 system in a way that is feasible to deliver it to specific tissues via a viral vector," said senior author Dr. Gene Yeo, professor of cellular and molecular medicine at the University of California, San Diego. "The main thing we do not know yet is whether or not the viral vectors that deliver RCas9 to cells would elicit an immune response. Before this could be tested in humans, we would need to test it in animal models, determine potential toxicities and evaluate long-term exposure."

Related Links:
University of California, San Diego

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The cobas Malaria test is the first FDA-approved molecular test to screen U.S. blood donors for malaria (Photo courtesy of Roche)

First FDA-Approved Molecular Test to Screen Blood Donors for Malaria Could Improve Patient Safety

Malaria, a serious illness that often leads to death, is spread by a specific mosquito species that infect humans with a parasite. Other transmission modes include blood transfusions, organ transplants,... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The medical office procedure detects the key biomarker in Parkinson’s and related neurodegenerative diseases (Photo courtesy of BIDMC)

Simple Skin Biopsy Test Detects Parkinson’s and Related Neurodegenerative Diseases

Parkinson's disease and a group of related neurodegenerative disorders known as synucleinopathies impact millions globally. These conditions, including Parkinson’s disease (PD), dementia with Lewy bodies... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.